Colorectal Cancer

Episodes 1-8 of 8

• 

  RestartResume

  Case Consult: Current Standards and Emerging Directions in BRAF-Mutant mCRC Care

  RestartResume

  Case Consult: Current Standards and Emerging Directions in BRAF-Mutant mCRC Care

  MinuteCE®

  Case Consult: Current Standards and Emerging Directions in BRAF-Mutant mCRC Care

  1.00 program credit

  • 

    

    Scott Kopetz, MD, PhD

  • 

    

    Cathy Eng, MD, FACP

  1.00 program credit

• 

  RestartResume

  Advancing Molecular Therapies to First Line in BRAF-Mutated mCRC: Insights From Emerging Data

  RestartResume

  Advancing Molecular Therapies to First Line in BRAF-Mutated mCRC: Insights From Emerging Data

  MinuteCE®

  Advancing Molecular Therapies to First Line in BRAF-Mutated mCRC: Insights From Emerging Data

  1.00 program credit

  • 

    

    Scott Kopetz, MD, PhD

  • 

    

    Cathy Eng, MD, FACP

  1.00 program credit

• 

  RestartResume

  Maximizing Outcomes: Strategic Approaches in Metastatic CRC Treatment

  RestartResume

  Maximizing Outcomes: Strategic Approaches in Metastatic CRC Treatment

  MinuteCE®

  Maximizing Outcomes: Strategic Approaches in Metastatic CRC Treatment

  1.00 program credit

  • 

    

    Scott Kopetz, MD, PhD

  • 

    

    Cathy Eng, MD, FACP

  1.00 program credit

• 

  RestartResume

  Mutational Testing in mCRC: Methods and Data Driving Treatment Selection

  RestartResume

  Mutational Testing in mCRC: Methods and Data Driving Treatment Selection

  MinuteCE®

  Mutational Testing in mCRC: Methods and Data Driving Treatment Selection

  1.00 program credit

  • 

    

    Fortunato Ciardiello, MD, PhD

  • 

    

    Jenny Seligmann, MBChB, PhD

  1.00 program credit

• 

  RestartResume

  From Guidelines to Practice: First-Line Treatment Choices in mCRC

  RestartResume

  From Guidelines to Practice: First-Line Treatment Choices in mCRC

  MinuteCE®

  From Guidelines to Practice: First-Line Treatment Choices in mCRC

  1.00 program credit

  • 

    

    Fortunato Ciardiello, MD, PhD

  • 

    

    Jenny Seligmann, MBChB, PhD

  1.00 program credit

• 

  RestartResume

  Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond

  RestartResume

  Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond

  MinuteCE®

  Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond

  1.00 program credit

  • 

    

    Fortunato Ciardiello, MD, PhD

  • 

    

    Jenny Seligmann, MBChB, PhD

  1.00 program credit

• 

  MinuteCE®

  Mastering Mutation-Driven mCRC: From Testing to Targeted Therapy

  1.00 credit 8 episodes

  • 

    

    Jenny Seligmann, MBChB, PhD

  • 

    

    Fortunato Ciardiello, MD, PhD

  • 

    

    Scott Kopetz, MD, PhD

  • 

    

    Cathy Eng, MD, FACP

  1.00 credit 8 episodes

• 

  RestartResume

  Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes    

  RestartResume

  Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes    

  MinuteCE®

  Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes    

  1.00 program credit

  • 

    

    Fortunato Ciardiello, MD, PhD

  • 

    

    Jenny Seligmann, MBChB, PhD

  1.00 program credit